Stanford researchers have discovered a naturally occurring molecule, BRP, that reduces appetite and body weight in animals similarly to semaglutide (Ozempic) but without its common side effects like nausea and muscle loss. Using AI, they identified BRP from a pool of prohormones, showing it activates distinct brain pathways and may offer a more targeted, tolerable obesity treatment. (Artists concept).A Stanford Medicine study used artificial intelligence to discover a naturally occurring molecule, specifically, a peptide, that reduced appetite and promoted weight loss in both mice and pigs.Researchers at Stanford Medicine have identified a naturally occurring molecule that mimics the appetite-suppressing and weight-reducing effects of semaglutide, the active ingredient in Ozempic. In animal studies, this molecule, called BRP, demonstrated similar benefits without some of semaglutides common side effects, such as nausea, constipation, and significant muscle loss.BRP works through a distinct but related metabolic pathway and activates different neurons in the brain, suggesting it may offer a more precise and potentially safer approach to weight management.The receptors targeted by semaglutide are found in the brain but also in the gut, pancreas, and other tissues, said assistant professor of pathology Katrin Svensson, PhD. Thats why Ozempic has widespread effects including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism.The 12-amino-acid BRP peptide (spheres are atoms and sticks are bonds) suppresses appetite and reduces weight gain in mice and pigs without causing nausea or food aversion. Credit: Katrin SvenssonSvensson, the senior author of the study published on March 5 in Nature, has co-founded a company to begin clinical trials of the newly discovered molecule in humans in the near future. The studys lead author is Laetitia Coassolo, PhD, a senior research scientist.The research was made possible by the use of artificial intelligence, which helped analyze dozens of proteins from a class known as prohormones. Prohormones are biologically inert molecules that become active when they are cleaved by other proteins into smaller pieces called peptides; some of these peptides then function as hormones to regulate complex biological outcomes, including energy metabolism, in the brain and other organs.Each prohormone can be divided in a variety of ways to create a plethora of functional peptide progeny. But with traditional methods of protein isolation, its difficult to pick peptide hormones (which are relatively rare) out of the biological soup of the much more numerous natural byproducts of protein degradation and processing.The researchers focused on the prohormone convertase 1/3, which separates prohormones at specific amino acid sequences and is known to be involved in human obesity. One of the peptide products is glucagon-like peptide 1, or GLP-1, which regulates appetite and blood sugar levels; semaglutide works by mimicking the effect of GLP-1 in the body. The team turned to artificial intelligence to help them identify other peptides involved in energy metabolism.Peptide PredictorInstead of manually isolating proteins and peptides from tissues and using techniques like mass spectrometry to identify hundreds of thousands of peptides, the researchers designed a computer algorithm they named Peptide Predictor to identify typical prohormone convertase cleavage sites in all 20,000 human protein-coding genes. They then focused on genes that encode proteins that are secreted outside the cell a key characteristic of hormones and that have four or more possible cleavage sites. Doing so narrowed down the search to 373 prohormones, a manageable number to screen for their biological effects.Katrin Svensson. Credit: Stanford UniversityThe algorithm was absolutely key to our findings, Svensson said.Peptide Predictor predicted that prohormone convertase 1/3 would generate 2,683 unique peptides from the 373 proteins. Coassolo and Svensson focused on sequences likely to be biologically active in the brain. They screened 100 peptides, including GLP-1, for their ability to activate lab-grown neuronal cells.As expected, the GLP-1 peptide had a robust effect on the neuronal cells, increasing their activity threefold over control cells. But a small peptide made up of just 12 amino acids bumped up the cells activity tenfold over controls. The researchers named this peptide BRP based on its parent prohormone, BPM/retinoic acid inducible neural specific 2, or BRINP2 (BRINP2-related-peptide).When the researchers tested the effect of BRP on lean mice and minipigs (which more closely mirror human metabolism and eating patterns than mice do) they found that an intramuscular injection of BRP prior to feeding reduced food intake over the next hour by up to 50% in both animal models. Obese mice treated with daily injections of BRP for 14 days lost an average of 3 grams due almost entirely to fat loss while control animals gained about 3 grams over the same period. The mice also demonstrated improved glucose and insulin tolerance.Behavioral studies of the mice and pigs found no differences in the treated animals movements, water intake, anxiety-like behavior, or fecal production. And further studies of physiological and brain activity showed that BRP activates metabolic and neuronal pathways separate from those activated by GLP-1 or semaglutide.The researchers hope to identify the cell-surface receptors that bind BRP and to further dissect the pathways of its action. They are also investigating how to help the peptides effects last longer in the body to allow a more convenient dosing schedule if the peptide proves to be effective in regulating human body weight.The lack of effective drugs to treat obesity in humans has been a problem for decades, Svensson said. Nothing weve tested before has compared to semaglutides ability to decrease appetite and body weight. We are very eager to learn if it is safe and effective in humans.Reference: Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide by Laetitia Coassolo, Niels B. Danneskiold-Samse, Quennie Nguyen, Amanda Wiggenhorn, Meng Zhao, David Cheng-Hao Wang, David Toomer, Jameel Lone, Yichao Wei, Aayan Patel, Irene Liparulo, Deniz Kavi, Lianna W. Wat, Saranya Chidambaranathan Reghupaty, Julie Jae Kim, Tina Asemi, Ewa Bielczyk-Maczynska, Veronica L. Li, Maria Dolores Moya-Garzon, Nicole A. J. Krentz, Andreas Stahl, Danny Hung-Chieh Chou, Liqun Luo and Katrin J. Svensson, 5 March 2025, Nature.DOI: 10.1038/s41586-025-08683-yResearchers from the University of California, Berkeley; the University of Minnesota; and the University of British Columbia contributed to the work.The study was funded by the National Institutes of Health (grants R01DK125260, P30DK116074, K99AR081618 and GM113854), the SPARK Translational Research Program at Stanford, Stanford Bio-X, the Stanford Maternal and Child Health Research Institute, the American Heart Association, a Stanford Medicine Deans Fellowship Award, the Carlsberg Foundation, and the Wu Tsai Human Performance Alliance.Svensson and Coassolo are inventors on patents regarding BRP peptides for metabolic disorders. Svensson is a co-founder of Merrifield Therapeutics.